Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the human host can lead to various clinical manifestations, from symptomless carriers to mild to moderate to severe/critical illness. Therefore, the clinical classification of SARS-CoV-2 disease, based on severity, is a reliable way to predict disease states in SARS-CoV-2 infection. Recent studies on genomics, transcriptomics, epigenomics, and immunogenomics, along with spatial analysis of immune cells have delineated and defined the categorization of these disease groups using these high throughout technologies. These technologies hold the promise of providing not only a detailed but a holistic view of SARS-CoV-2-led pathogenesis. The main genomic, cellular, and immunologic features of each disease category, and what separates them spatially and molecularly are discussed in this brief review to provide a foundational spatial understanding of SARS-CoV-2 immunopathogenesis.

Keywords

Severe acute respiratory syndrome coronavirus-2 / anti-viral immunity / genomics / interferons / immune cells / tropism

References

[1] Rolling updates on coronavirus disease (COVID-19) [Internet]. World Health Organization; c2022 [cited 2020 Dec 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

[2] Epidemiological alert: novel coronavirus (nCoV) - 16 January 2020 [Internet]. Pan American Health Organization; [cited 2020 Jan 16]. Available from: https://www.paho.org/en/documents/epidemiological-alert-novel-coronavirus-ncov-16-january-2020

[3] COVID-19 coronavirus pandemic [Internet]. Worldometers.info; [cited 2022 Dec 3]. Available from: https://www.worldometers.info/coronavirus/

[4] Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Can. 2020; 5: 223-34.

[5] Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D. Dysregulation of cell signaling by SARS-CoV-2. Trends Microbiol. 2021; 29: 224-37.

[6] To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021; 10: 507-35.

[7] Schubert K, Karousis ED, Jomaa A, Scaiola A, Echeverria B, Gurzeler LA, et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat Struct Mol Biol. 2020; 27: 959-66. Erratum in: Nat Struct Mol Biol. 2020; 27:1094.

[8] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181: 281-92.E6. Erratum in: Cell. 2020;183:1735.

[9] Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020; 39: 198-216.

[10] Littler DR, Gully BS, Colson RN, Rossjohn J. Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9. iScience. 2020; 23: 101258.

[11] Slanina H, Madhugiri R, Bylapudi G, Schultheiß K, Karl N, Gulyaeva A, et al. Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proc Natl Acad Sci U S A. 2021; 118: e2022310118.

[12] Gadhave K, Kumar P, Kumar A, Bhardwaj T, Garg N, Giri R. Conformational dynamics of 13 amino acids long nsp11 of SARS-CoV-2 under membrane mimetics and different solvent conditions. Microb Pathog. 2021; 158: 105041.

[13] Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020; 584: 154-6.

[14] Arya R, Kumari S, Pandey B, Mistry H, Bihani SC, Das A, et al. Structural insights into SARS-CoV-2 proteins. J Mol Biol. 2021; 433: 166725.

[15] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-ncov spike in the prefusion conformation. Science. 2020; 367: 1260-3.

[16] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271-80.E8.

[17] Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-Ronen Y, et al. The coding capacity of SARS-CoV-2. Nature. 2021; 589: 125-30.

[18] Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. The molecular virology of coronaviruses. J Biol Chem. 2020; 295: 12910-34.

[19] Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014; 109: 97-109.

[20] Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus disease 2019 case surveillance - United States, january 22-may 30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 759-65.

[21] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA. 2020; 323: 1239-42.

[22] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-ncov and naming it SARS-CoV-2 . Nat Microbiol. 2020; 5: 536-44.

[23] Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19: 409-24.

[24] Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta). Clin Infect Dis. 2022; 75: e1128-36.

[25] Tracking SARS-CoV-2 variants [Internet]. World Health Organization. c2022 [cited 2021 Jul 20]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

[26] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506. Erratum in: Lancet. 2020; 395:496.

[27] Karki R, Kanneganti TD. The ‘cytokine storm’: molecular mechanisms and therapeutic prospects. Trends Immunol. 2021; 42: 681-705.

[28] Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022; 23: 165-76.

[29] Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021; 16: e0247461.

[30] Kanneganti TD. Intracellular innate immune receptors: life inside the cell. Immunol Rev. 2020; 297: 5-12.

[31] Saksena N, Bonam SR, Miranda-Saksena M . Epigenetic lens to visualize the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in COVID-19 pandemic. Front Genet. 2021; 12: 581726.

[32] Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017; 38: 771-93.

[33] Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Rep Med. 2020; 1: 100016.

[34] Zhang Q, Cao X. Epigenetic regulation of the innate immune response to infection. Nat Rev Immunol. 2019; 19: 417-32.

[35] Haller O, Weber F. Pathogenic viruses: smart manipulators of the interferon system. Curr Top Microbiol Immunol. 2007; 316: 315-34.

[36] Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020; 181: 1036-45.E9.

[37] Burke JM, St Clair LA, Perera R, Parker R. SARS-CoV-2 infection triggers widespread host mrna decay leading to an mRNA export block. RNA. 2021; 27: 1318-29.

[38] Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583: 459-68.

[39] McClenaghan C, Hanson A, Lee SJ, Nichols CG. Coronavirus proteins as ion channels: current and potential research. Front Immunol. 2020; 11: 573339.

[40] Carrasco L. Modification of membrane permeability by animal viruses. Adv Virus Res. 1995; 45: 61-112.

[41] Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, et al.; USFQ-COVID19 Consortium; Nakagawa S, Sato K. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 2020; 32: 108185.

[42] Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020; 286: 198074.

[43] Chen K, Xiao F, Hu D, Ge W, Tian M, Wang W, et al. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-β production. Viruses. 2020; 13: 47.

[44] Wu J, Shi Y, Pan X, Wu S, Hou R, Zhang Y, et al. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep. 2021; 34: 108761.

[45] Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020; 369: 1249-55.

[46] Hsu JC, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci U S A. 2021; 118: e2101161118.

[47] Schäfer A, Baric RS. Epigenetic landscape during coronavirus infection. Pathogens. 2017; 6: 8.

[48] Chamberlain LH, Shipston MJ. The physiology of protein S-acylation . Physiol Rev. 2015; 95: 341-76.

[49] Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019; 10: 50.

[50] Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021; 218: e20201707.

[51] Wei M, Wang L, Wu T, Xi J, Han Y, Yang X, et al. NLRP3 activation was regulated by DNA methylation modification during Mycobacterium tuberculosis infection . Biomed Res Int. 2016; 2016: 4323281.

[52] Shah A. Novel coronavirus-induced nlrp3 inflammasome activation: a potential drug target in the treatment of COVID-19. Front Immunol. 2020; 11: 1021.

[53] Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al.; ISB-Swedish COVID19 Biobanking Unit; Wei W, Price ND, Huang S, Subramanian N, Wang K, Magis AT, et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell. 2020; 183: 1479-95.E20.

[54] Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020; 182: 59-72.E15.

[55] Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al.; Yale IMPACT Team; Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Dela Cruz C, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020; 584: 463-9.

[56] Stone MR, O’Neill A, Lovering RM, Strong J, Resneck WG, Reed PW, et al. Absence of keratin 19 in mice causes skeletal myopathy with mitochondrial and sarcolemmal reorganization. J Cell Sci. 2007; 120: 3999-4008.

[57] Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11: 827.

[58] Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al.; UPenn COVID Processing Unit; Betts MR, Meyer NJ, Wherry EJ. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020; 369: eabc8511.

[59] Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4⁺ and CD8⁺ T cells in adults . Am J Respir Crit Care Med. 2010; 181: 1407-17.

[60] Zhou J, Kaiser A, Ng C, Karcher R, McConnell T, Paczkowski P, et al. CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay. Hum Vaccin Immunother. 2017; 13: 1625-9.

[61] Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989; 74: 2527-34.

[62] Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011; 11: 762-74.

[63] Kratofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and injury. Arterioscler Thromb Vasc Biol. 2017; 37: 35-42.

[64] Matlho K, Wang XM, Conceicao V, Perera SS, Wang B, Soedjono M, et al. CD14+CD16-low monocyte subset predicts non-pro-gressive HIV disease: evidence of a new prognostic and diagnostic biomarker. Biomark Applic. 2018; 2018.

[65] Schulte-Schrepping J, Reusch N, Paclik D, Baβler K, Schlickeiser S, Zhang B, et al. ; Deutsche COVID-19 OMICS Initiative (DeCOI). Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020; 182: 1419-40.E23.

[66] Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martíƴnez-Colón GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020; 26: 1070-6.

[67] Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, et al. Roles of natural killer cells in antiviral immunity. Curr Opin Virol. 2016; 16: 15-23.

[68] Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, et al. ; Karolinska COVID-19 Study Group. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020; 5: eabd6832.

[69] Demaria O, Carvelli J, Batista L, Thibult ML, Morel A, André P, et al. Identification of druggable inhibitory immune checkpoints on natural killer cells in COVID-19. Cell Mol Immunol. 2020; 17: 995-7.

[70] Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021; 600: 295-301.

[71] Narni-Mancinelli E, Vivier E. Clues that natural killer cells help to control COVID. Nature. 2021; 600: 226-7.

[72] Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garcíƴa R, et al.; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner AC, Schultze JL, Nattermann J. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021; 54: 2650-69.E14.

[73] Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol. 2019; 3: 77-103.

[74] Perera SS, Wang B, Damian A, Dyer W, Zhou L, Conceicao V, et al. Retrospective proteomic analysis of cellular immune responses and protective correlates of p24 vaccination in an HIV elite controller using antibody arrays. Microarrays (Basel). 2016; 5: 14.

[75] Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020; 369: 718-24.

[76] Deng X, Zhang Y, Li M, Tang X, Shen J, Chen Y, et al. Dynamic response landscape of immune cells identified immune dysfunction which predicts disease progression in COVID-19 infected patients. Int J Biol Sci. 2022; 18: 3066-81.

[77] Bonam SR, Chauvin C, Mathew MJ, Bayry J. IFN-γ induces PD-L1 expression in primed human basophils. Cells. 2022; 11: 801.